Kforce unloads clinical research business; Illumina urging Roche rejection;

@FierceBiotech: RNAi, smuggled in a virus, weakens tumors before final radiation blow. More | Follow @FierceBiotech

@JohnCFierce: Note to pessimists: Maybe the sky isn't falling. Thoughts on the VC apocalypse. Piece | Follow @JohnCFierce

@RyanMFierce: Versant Ventures has named Roche vet Guido Magni a venture partner to aid Euro life sciences practice. Release | Follow @RyanMFierce

@FierceMedDev: White House OKs medical device act. News | Follow @FierceMedDev

>  Staffing company Kforce is selling its clinical research business to CRO InVentiv Health for $50 million in cash and will focus instead on its core business, Reuters reports. Story

> Illumina ($ILMN) is urging stockholders at its April 18 annual meeting to reject Roche's ($RHHBY) unsolicited offer for the molecular diagnostics company. Release

> The FDA is voicing safety concerns over Talon Therapeutics' Mariqbo drug for associated peripheral neuropathy, because 15 patients have died during clinical trials, biotech analyst Adam Feuerstein Tweeted. Story

> NicOx SA stock jumped 11% last week, reaching the biggest weekly gain ever in Paris trading, Bloomberg reports, based on optimism over mid-stage clinical trial results for a glaucoma drug licensed to Bausch & Lomb. Story

> Canadian biotech QLT gained U.S. orphan drug status for Visudyne, which it is testing to treat chronic or recurrent central serous chorioretinopathy. The drug is already approved to treat age-related macular degeneration. Story

> Provectus Pharmaceuticals says it generated top line Phase I data in the first randomized controlled trial for its psoriasis treatment. Release

Pharma News

@FiercePharma: Pharma opportunity: Figure out how to get women to adhere to scripts, and docs to prescribe to women on par with men. Article | Follow @FiercePharma

> Abbott execs take pay cuts, but White still nabs $24M. More

> Treatment gap: Women get fewer standard heart drugs. Story

> Roche exec expects 'limited' rebound for pharma. Article

IT News

> Stanford algorithm uncovers drug side effects. Story

> Biomatters taps Ammundsen as CEO. Item

> GSK strikes deal to listen in on social media chatter. Article

> Medidata lauded on Wall Street; CEO takes shot at rival Oracle. More

Medical Device News

> Kensey Nash, St. Jude wrap up Angio-Seal dispute. Article

> Akili envisions video game as therapeutic device. Item

> Covidien scoops up pulmonary devicemaker for $300M. News

> i2Eye jumps into visual testing world. Story

And Finally... Guido Magni is joining Versant Ventures as a venture partner with a focus on innovative startups. He previously managed EuroVentures, a Versant biotech incubator. Release

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.